| [1] |
Fabien P, Borger Michael A, Jonas L, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2025, 46(44):4635-4736.
|
| [2] |
潘文志, 翁梓珑, 周达新, 等. 《2025年ESC/EACTS瓣膜性心脏病管理指南》更新要点解读[J/OL]. 中华心脏与心律电子杂志, 2025, 13(3):129-135.
|
| [3] |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632.
|
| [4] |
Tam DY, Wijeysundera HC, Naimark D, et al. Impact of transcatheter aortic valve durability on life expectancy in low-risk patients with severe aortic stenosis[J]. Circulation, 2020, 142(4):354-364.
|
| [5] |
Leon Martin B, Mack Michael J, Philippe P, et al. Transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years[J]. N Engl J Med, 2026, 394(8):773-783.
|
| [6] |
中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版)[J]. 中国介入心脏病学杂志, 2020, 28(6):301-309.
|
| [7] |
中国医师协会心血管内科医师分会结构性心脏病学组, 周达新, 吴永健, 等. 单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J]. 中国介入心脏病学杂志, 2023, 31(11):801-809.
|
| [8] |
Lønborg J, Jabbari R, Sabbah M, et al. PCI in patients undergoing transcatheter aortic-valve implantation[J]. N Engl J Med, 2024, 391(23):2189-2200.
|
| [9] |
Patterson T, Clayton T, Dodd M, et al. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): a randomized clinical trial[J]. JACC Cardiovasc Interv, 2021, 14(18):1965-1974.
|
| [10] |
Kobari Y, Inohara T, Tsuruta H, et al. No Antithrombotic therapy after transcatheter aortic valve replacement: insight from the OCEAN-TAVI Registry[J]. JACC Cardiovasc Interv, 2023, 16(1):79-91.
|
| [11] |
Blankenberg S, Seiffert M, Vonthein R, et al. Transcatheter or surgical treatment of aortic-valve stenosis[J]. N Engl J Med, 2024, 390(17):1572-1583.
|
| [12] |
Forrest JK, Deeb GM, Yakubov SJ, et al. 4-Year outcomes of patients with aortic stenosis in the Evolut low risk trial[J]. J Am Coll Cardiol, 2023, 82(22):2163-2165.
|
| [13] |
Sievers H, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens[J]. J Thorac Cardiovasc Surg, 2007, 133(5):1226-1233.
|
| [14] |
Li W, Jia Y, Li H, et al. Long-term outcomes of BAV-0 patients compared with BAV-1 and TAV patients after TAVR[J]. JACC Cardiovasc Interv, 2025, 18(15):1881-1892.
|
| [15] |
Yamanaka F, Shishido K, Moriyama N, et al. Incidence and prognosis of prosthesis-patient mismatch after transcatheter aortic valve replacement for bicuspid aortic stenosis[J]. JACC Cardiovasc Interv, 2025, 18(4):492-502.
|
| [16] |
Sergio R, Amat-Santos Ignacio J, Xavier R, et al. Dapagliflozin in patients undergoing transcatheter aortic-valve implantation[J]. N Engl J Med, 2025, 392(14):1396-1405.
|
| [17] |
Clara B, Sergio GB, Ignacio A, et al. Effect of dapagliflozin on quality of life of patients with aortic stenosis undergoing transcatheter aortic valve implantation[J]. J Am Coll Cardiol, 2025, 86(15):1128-1138.
|
| [18] |
Makkar RR, Gupta A, Waggoner TE, et al. Cerebral embolic protection by geographic region: a post hoc analysis of the PROTECTED TAVR randomized clinical trial[J]. JAMA Cardiol, 2025, 10(1):17-24.
|
| [19] |
Kharbanda RK, Kennedy J, Jamal Z, et al. Routine cerebral embolic protection during transcatheter aortic-valve implantation[J]. N Engl J Med, 2025, 392(24):2403-2412.
|
| [20] |
Hans-Josef F, Joerg E, Philipp L, et al. Peri-interventional anesthesia strategies for transcatheter aortic valve implantation: a multicenter, randomized, controlled, noninferiority trial[J]. Circulation, 2025, 152(22):1526-1537.
|
| [21] |
Wire B. Caranx medical announces first clinical use of the TAVIPILOT soft, cleared by FDA for commercial in July: the world first AI software for real-time intra-operative guidance of transcatheter heart valve implantation [EB/OL]. Nov 17, 2025.
URL
|
| [22] |
中国医师协会心血管内科医师分会结构性心脏病专业委员, 中华医学会心血管病学分会结构性心脏病学组. 经导管主动脉瓣置换术中国专家共识[J]. 中国介入心脏病学杂志, 2015, 23(12):661-667.
|
| [23] |
国家放射与治疗临床医学研究中心, 苏州工业园区东方华夏心血管健康研究院, 周达新等. 经导管主动脉瓣置换术中国专家共识(2025版)[J]. 中国介入心脏病学杂志, 2025, 33(12):661-674.
|
| [24] |
Pan W, Chen S, Li W, et al. Early results of multicenter trial of a novel balloon-expandable valve with anchor for aortic regurgitation[J]. JACC Cardiovasc Interv, 2025, 18(6):752-764.
|
| [25] |
Li R, Wang L, Liu Q, et al. Comparative study of single- versus double-ProGlide device strategy for access site closure of transfemoral transcatheter aortic valve replacement[J]. Catheter Cardiovasc Interv, 2025, 106(3):1639-1649.
|
| [26] |
Yang C, Qingrong L, Hongliang Z, et al. Transcatheter aortic valve replacement with a fully-recyclable self-expanding short-frame sciencrown valve for severe aortic stenosis[J]. Int J Surg, 2026, 112(2):3338-3347.
|
| [27] |
Yao J, Wu D, Yan Y, et al. Redefining TAVR valve sizing: a validated multiplanar approach for both bicuspid and tricuspid valves[J]. JACC Cardiovasc Interv, 2025, 18(14):1748-1757.
|
| [28] |
严道医声网. TCT 2025·中国之声｜王焱教授重磅发布全球首个机器人辅助经导管主动脉瓣置换术可行性临床试验结果[EB/OL]. (2025-10-29) [2026-03-28].
URL
|
| [29] |
Yang L, Chen S, Zhang X, et al. Comparisons of noncoronary sinus pivot implantation (NCPI) and conventional method for transcatheter aortic valve replacement with self-expanding valve in pure aortic regurgitation (PAR)[J]. Catheter Cardiovasc Interv, 2024, 103(7):1093-1100.
|
| [30] |
Yang L, Weng Z, Chen S, et al. Noncoronary sinus pivot implantation for transcatheter aortic valve replacement with self-expanding valve for aortic regurgitation[J]. JACC Asia, 2025, 5(7):884-894.
|
| [31] |
杨力凡, 翁梓珑, 林大卫, 等. 无冠窦支点植入法治疗单纯主动脉瓣反流:一项单中心队列研究的1年疗效与安全性评估[J/OL]. 上海医学, 1-10[2026-03-28].
URL
|
| [32] |
Feng X, XinJing C, ZiLong W, et al. Noncoronary sinus pivot implantation (NCPI) strategy for transcatheter aortic valve replacement with self-expanding valve in pure native aortic regurgitation: a multicenter, registry study from the CCA database-NTCVR[J]. Catheter Cardiovasc Interv, 2025, 106(6):3230-3238.
|